Liver cancer is one of the most common malignant tumors in the world, and the number of liver cancer patients in my country accounts for more than half of the world.

It is estimated that 70 to 80 percent of patients with liver cancer are already in the middle or late stage at the time of diagnosis.

People need only about a quarter of liver can meet daily needs. Therefore, in the early stage of liver cancer, the liver can still work normally, and people do not feel obvious discomfort. By the time people notice it , the liver is already devastated.

Of course, most cancers, not just liver cancer, are insidious in their early stages. So it's really important to develop an awareness of early screening!

Cancer can be prevented and screened early

In 2011, the World Health Organization suggested that one-third of all cancers are entirely preventable; A third of cancers can be cured by early detection; One third of with all cancers, patients’ life can be prolonged, painless and improve the quality of life with existing treatments.

This means that there is time and opportunity to take preventive and early screening measures to prevent or reduce the incidence of malignancy.

Screening age: male ≥40 years, female ≥50 years; People should be checked every 6 months.

Tumor marker detection is a method with strong operability and applicability, among which, alpha- fetoprotein (AFP) can be used to screen patients at high risk of primary liver cancer.

What is alpha-fetoprotein?

Alpha-fetoprotein (AFP) is an acidic glycoprotein found in the blood of a fetus. After birth, alpha- fetoprotein in the blood drops rapidly, returning to normal level within a few months to a year. The normal human level is very low.

However, when liver cells become cancerous, they recover producing the protein, and as the disease progresses, its level in the serum increases dramatically.

Therefore, alpha-fetoprotein has become a specific tumor marker in the diagnosis of primary liver cancer, which has the role of establishing diagnosis, early diagnosis and Identification diagnosis.

Clinical application of alpha-fetoprotein

The Health Industry Standard of the People's Republic of China clearly states that:

01Serum AFP combined with liver ultrasound can be used to Serum AFP combined with liver ultrasonography can be used as a screening for high-risk groups of primary liver cancer.

02Serum AFP is the most commonly used tumor marker in clinical diagnosis of primary hepatocellular carcinoma (HCC).

03For serum AFP≥400μg /L over 1 month, or ≥200μg /L for 2 months, liver cancer should be highly suspected after excluding pregnancy, active liver disease and embryo-derived tumors of the germ line. B-ultrasound examination, CT/MRI and biopsy should be performed when necessary to confirm the diagnosis.

04Serum AFP is an important marker to judge the prognosis of primary liver cancer. High concentration of SERUM AFP indicates poor prognosis.

05Serum AFP can be used for follow-up and recurrence monitoring of patients with liver cancer after surgical resection or liver transplantation. It should be tested every 3 months within 2 years after surgery and every 6 months within 3 to 5 years.

What does the high-risk liver cancer crowd include?

Infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV); Excessive drinking;

Nonalcoholic steatohepatitis;

Long-term consumption of food contaminated with aflatoxins; Cirrhosis due to various other causes;
Family history of liver cancer.

Hangzhou Laihe Biotech Co., Ltd AFP assay reagents (fluorescence immunochromatography) are used for quantitative determination of AFP in human serum or plasma samples in vitro. It is mainly used for dynamic monitoring of malignant tumor patients to assist in judging the disease process or treatment effect.

This reagent adopts double antibody sandwich method. The test area (T) of the kit contains prefixed alpha-fetoprotein monoclonal antibody, the quality control area (C) contains sheep anti-rabbit IgG, and the detection buffer contains fluorescent markers of alpha-fetoprotein monoclonal antibody and rabbit IgG.